CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,897,302 | -23.5% | 41,800 | -5.4% | 0.00% | -55.6% |
| Q2 2023 | $2,481,388 | +46.3% | 44,200 | +17.9% | 0.01% | -64.0% |
| Q1 2023 | $1,696,125 | -43.4% | 37,500 | -49.1% | 0.02% | -54.5% |
| Q4 2022 | $2,994,198 | +51.8% | 73,658 | +143.9% | 0.06% | +44.7% |
| Q3 2022 | $1,973,000 | +142.1% | 30,200 | +52.1% | 0.04% | -20.8% |
| Q3 2019 | $815,000 | +98.8% | 19,855 | +128.2% | 0.05% | +6.7% |
| Q2 2019 | $410,000 | +24.6% | 8,700 | -5.4% | 0.04% | -16.7% |
| Q1 2019 | $329,000 | – | 9,200 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |